DDrare: Database of Drug Development for Rare Diseases

Botulinum toxin type b (myobloc) (DrugBank: Botulinum Toxin Type B)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
6	パーキンソン病	1

2. 筋萎縮性側索硬化症　［臨床試験数：508，薬物数：530（DrugBank：146），標的遺伝子数：170，標的パスウェイ数：221］

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 508 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00125203 (ClinicalTrials.gov)	July 2003	27/7/2005	Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)	A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis;Sialorrhea	Drug: Botulinum toxin type B (Myobloc);Procedure: Injection of salivary glands	The University of Texas Health Science Center at San Antonio	ALS Association;University of Kansas;Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System	Completed	21 Years	85 Years	Both	20	Phase 2;Phase 3	United States

6. パーキンソン病　［臨床試験数：2,123，薬物数：2,046（DrugBank：324），標的遺伝子数：183，標的パスウェイ数：198］

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,123 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00515437 (ClinicalTrials.gov)	July 2007	10/8/2007	A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients	A Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients	Drooling	Biological: Botulinum Toxin Type B (Myobloc);Biological: Matched placebo to Myobloc	Solstice Neurosciences	NULL	Completed	18 Years	85 Years	All	54	Phase 2	United States